NCT02750358 2025-06-22Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast CancerMemorial Sloan Kettering Cancer CenterPhase 2 Active not recruiting50 enrolled